8-K: Shuttle Pharmaceuticals Completes $790,000 Convertible Note and Warrant Offering

Shuttle Pharmaceuticals Holdings, Inc. has finalized a $790,000 offering of convertible notes and warrants, including a significant investment from its CEO.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. completed a previously announced offering of senior secured convertible notes and warrants.
• The offering, which aimed to raise up to $1.3 million, closed with total gross proceeds of $790,000.
• The first closing on October 14, 2024, secured $600,000, including $237,500 from the company's CEO, Dr. Anatoly Dritschilo.
• The second closing on October 21, 2024, added $231,579 in notes and warrants, resulting in an additional $220,000 in proceeds.
• Two accredited investors participated in the second closing, purchasing notes and 88,544 warrants exercisable at $1.49 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully raised capital, although less than initially targeted. The CEO's investment is a strong positive signal.

Positives

• The company successfully completed the offering, securing $790,000 in gross proceeds.
• The CEO's investment demonstrates confidence in the company's prospects.
• The offering attracted investment from accredited investors.

Negatives

• The total proceeds of $790,000 were less than the initially targeted $1.3 million.

Risks

• The notes and warrants were not registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption.
• The company is relying on private placement exemptions, which may limit the pool of potential investors.

Future Outlook

The company has completed the offering and will likely use the funds for general corporate purposes and to advance its drug development programs.

Management Comments

• The document does not contain any direct quotes from management, but the CEO's investment indicates a positive outlook.

Industry Context

This type of financing is common for small biotech companies seeking to fund research and development. The use of convertible notes and warrants is a typical approach to attract investors.

Comparison to Industry Standards

• Many small biotech companies use convertible notes and warrants to raise capital, especially in early stages of development.
• The size of the raise, $790,000, is relatively small compared to larger biotech firms, but is typical for companies at this stage.
• The warrant exercise price of 125% of the prior day's closing price is a common structure to incentivize investors.

Related Party Transactions

• The CEO, Dr. Anatoly Dritschilo, invested $237,500 in the offering.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares upon conversion of the notes and exercise of the warrants.
• The capital raise provides the company with additional funding to support its operations and development programs.

Next Steps

• The company will likely use the proceeds from the offering for general corporate purposes and to advance its drug development programs.

Key Dates

Keywords

convertible notes, warrants, capital raise, private placement, Shuttle Pharmaceuticals, financing, equity securities